Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Ottignies-Louvain-La-Neuve – page 3

47 clinical trials in Ottignies-Louvain-La-Neuve, Belgium across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Ottignies-Louvain-La-Neuve at a glance
47
clinical trials
  • Paediatric trials0
  • Research sites1
Type of trial
Recruitment status
Quick filters

47 trials in Ottignies-Louvain-La-Neuve

Open in trial search

Breast cancer

Not yet recruiting

Study Comparing Imlunestrant with Standard Endocrine Therapy for Patients with Early ER+, HER2- Breast Cancer at Increased Risk of Recurrence

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Eli Lilly & Co.

Pneumonia

Not yet recruiting

Study on CAL02 and Sodium Chloride for Patients with Severe Community-Acquired Bacterial Pneumonia

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Cholesterol
  • Sponsor:Eagle Pharmaceuticals Inc.

Pneumonia

Not yet recruiting

Study of Baricitinib for Treating Hospital-Acquired Pneumonia in Critically Ill Patients with a Proinflammatory Profile

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Baricitinib
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Pneumonia+1

Not recruiting

A study testing trimodulin in hospitalized adult patients with community-acquired pneumonia including COVID-19 pneumonia

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Trimodulin (Human Igm, Iga, Igg Solution)
  • Sponsor:Biotest GmbH & Co. KGaA

Study Comparing Elacestrant and Standard Endocrine Therapy for Patients with Early Breast Cancer at High Risk of Recurrence

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:Stemline Therapeutics Inc.

Breast cancer+1

Not recruiting

Study of PF-07220060 and Fulvestrant for Adults with Advanced or Metastatic HR-positive, HER2-negative Breast Cancer After Previous Treatment

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Pfizer Inc.
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Anastrozole
  • Sponsor:AstraZeneca AB

Breast cancer female

Not recruiting

Study on Chemotherapy and Hormone Therapy for Women Over 70 with ER-Positive, HER2-Negative Breast Cancer Using Cyclophosphamide and Drug Combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Unicancer
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Buparlisib
  • Sponsor:Adlai Nortye USA Inc.

Pneumonia

Not recruiting

Study on Dexamethasone and Sodium Chloride for Treating Severe Hospital-Acquired Pneumonia in Critically Ill Patients with a Proinflammatory Profile

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sodium Chloride
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Study of Niraparib, Abiraterone Acetate, and Prednisone for Patients with Gene-Mutated Metastatic Castration-Sensitive Prostate Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Abiraterone
  • Sponsor:Janssen Cilag International

Breast cancer+2

Not recruiting

Study of Tucatinib, Trastuzumab, and Pertuzumab for Patients with Advanced or Metastatic HER2+ Breast Cancer

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Pertuzumab
  • Sponsor:Seagen Inc.

Other cities in Belgium

The busiest research cities in the country

All 170 cities in Belgium

Clinical research in Ottignies-Louvain-La-Neuve

What the registry says about research in the country

01 Hematology & Oncology Research

Groundbreaking clinical trials focusing on multiple myeloma treatments, specifically targeting patients with relapsed or refractory conditions. The research evaluates innovative combination therapies including talquetamab and daratumumab administration.

  • Blood Cancer Therapeutics
  • Novel Drug Combinations
  • Treatment Resistance

This comparative study aims to advance treatment options for patients who have undergone at least one prior line of therapy, potentially offering new hope for those with difficult-to-treat blood cancers.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.